|1.||Peloquin, Charles A: 7 articles (08/2013 - 08/2003)|
|2.||DuPont, Herbert L: 5 articles (11/2014 - 04/2005)|
|3.||Garey, Kevin W: 4 articles (06/2013 - 04/2005)|
|4.||Dorman, Susan E: 3 articles (01/2015 - 11/2008)|
|5.||Moro, Luigi: 3 articles (11/2014 - 03/2011)|
|6.||Weiner, Marc: 3 articles (11/2014 - 05/2005)|
|7.||Nuermberger, Eric L: 3 articles (08/2013 - 07/2006)|
|8.||Sterling, Timothy R: 3 articles (01/2013 - 03/2004)|
|9.||Burman, William: 3 articles (05/2010 - 05/2005)|
|10.||Murphy, Christopher K: 3 articles (07/2007 - 11/2006)|
09/01/2008 - "Compound 1, in combination with rifamycin, was especially effective in both infected human macrophages and in a murine model of infection. "
11/01/2006 - "Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection."
11/01/2012 - "A comparative kinetic study of rifamycin efficacy was then undertaken, and the results indicated that RPT clears latent 18b infection in mice faster than RIF. "
04/01/2008 - "The aim of this prospective randomized study was to verify the validity of topical rifamycin for prevention of post-VLC umbilical infections. "
06/01/2013 - "difficile was not shown to relate to prior use of a rifamycin drug or to acquiring the infection in the hospital, although the rate of overall resistance appeared to be rising."
01/31/1982 - "[Rheumatoid synovitis of the knee, treated successfully with intra-articular rifamycin SV]."
01/01/1993 - "This study was aimed to evaluate the usefulness of rifamycin SV as an agent for local treatment of rheumatoid synovitis. "
02/01/1987 - "Rifamycin SV in the local treatment of synovitis."
10/01/1985 - "Thus, local treatment with rifamycin SV alleviated but rarely abolished synovitis."
10/01/1985 - "Rifamycin SV in local treatment of synovitis--a clinical, arthroscopic and pharmacologic evaluation."
06/01/1985 - "Impaired plasma clearance of nicotinic acid and rifamycin-SV in Gilbert's syndrome: evidence of a functional heterogeneity."
04/01/1984 - "Plasma clearance of nicotinic acid and rifamycin-SV, and their interaction in Gilbert's syndrome: application of a compartmental model."
08/01/1990 - "Competition studies with combined administration of sulfobromophthalein (0.59 mumol/kg) and different doses of rifamycin SV (0.59, 1.47 and 2.95 mumol/kg) showed a significant (p less than 0.001) reduction in plasma disappearance rate in Gilbert's syndrome patients but not in controls. "
08/01/1990 - "The rifamycin SV dose at which a 50% inhibition in plasma disappearance rate was observed was 0.8 mumol/kg. The apparent affinity (Km) of the hepatic transport was higher in Gilbert's syndrome patients than in control subjects (3.61 +/- 0.37 mumol sulfobromophthalein/kg vs. 2.76 +/- 0.29 mumol sulfobromophthalein/kg, mean +/- S.D.; p less than 0.01), whereas no difference was found in Vmax (0.95 +/- 0.11 mumol sulfobromophthalein/kg vs. 0.93 +/- 0.10 mumol sulfobromophthalein/kg/min, mean +/- S.D.; N.S.).(ABSTRACT TRUNCATED AT 250 WORDS)"
06/01/1985 - "1. The plasma disappearance rate and the increment in plasma unconjugated bilirubin after intravenous administration of 5.9 mumol of rifamycin SV (RSV)/kg body wt. were investigated in 51 subjects with Gilbert's syndrome and 35 control subjects of both sexes. "
05/01/2010 - "A systematic review and meta-analysis of randomized, controlled trials and cohort studies was conducted to evaluate the impact of duration and dosing schedule of rifamycin and use of antiretroviral therapy in the treatment of active tuberculosis in HIV-positive patients. "
11/01/2009 - "For most patients, values for the area under the plasma concentration-time curve were as low or lower than those associated with treatment failure or relapse and with acquired rifamycin resistance in Tuberculosis Trials Consortium/US Public Health Service Study 23. "
07/01/2006 - "Recent studies have demonstrated that intermittent administration of rifamycin-based regimens results in higher rates of tuberculosis relapse and treatment failure compared with daily therapy. "
05/15/2005 - "A total of 102 (60%) of 169 patients in the treatment trial participated in the pharmacokinetic substudy, including 7 of 8 patients in whom tuberculosis treatment failure or relapse occurred in association with acquired rifamycin-resistant mycobacteria (hereafter, "ARR failure or relapse"). "
09/01/2014 - "Piero Sensi is probably known primarily for his role in the discovery of rifamycin and for developing it to be a drug of fundamental importance in the treatment of tuberculosis. "
|5.||Wounds and Injuries (Trauma)
01/01/1996 - "The causative agent was rifamycin SV used for cleaning the surgical wound prior to its closure. "
01/01/1976 - "The influence of rifamycin SV on the healing process of a wound was studied in animal experiments. "
06/01/2006 - "A patient developed severe anaphylaxis during irrigation of a wound with rifamycin SV. "
01/01/2003 - "Wound dressing, rifamycin eye drop until cicatrization, antibiotic and anti-inflammatory per os, are daily instituted for 10 days. "
02/01/2015 - "The aim of this study was to investigate the effects of topically applied fusidic acid and rifamycin on wound healing in a full-thickness wound model. "
|2.||rifaximin (L 105)
|3.||Niacin (Nicotinic Acid)
|2.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|3.||Directly Observed Therapy
|4.||Drug Therapy (Chemotherapy)
|5.||Highly Active Antiretroviral Therapy (HAART)